Caplin Point, via its subsidiaries, acquired 10 approved Injectable & Ophthalmic ANDAs from a multinational firm.

This strategically boosts its US portfolio, addressing a $473.2 million market, and includes oncology injectables for its new facility, with plans for international expansion.